Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective.
Anticancer medications
Availability
Medical institutions
National reimbursement drugs
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
14
06
2024
accepted:
13
08
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
21
8
2024
Statut:
epublish
Résumé
High clinical value national reimbursement anticancer medications (NRAMs) are pivotal treatments for patients with cancer. However, the availability of NRAMs in medical institutions is unknown. This study aimed to assess the availability of NRAMs in national and provincial medical institutions. This cross-sectional study utilized national health insurance data to access the availability of NRAMs in national and provincial medical institutions. Further statistical analyses and visualizations were conducted in terms of medical institution level and daily cost. Using the Spearman's rank correlation test (α = 0.05), we calculated the correlation between the availability rates of NRAMs and their negotiation access time, daily cost, per capita disposable income, provincial gross product, and number of policy releases. Overall, 81 NRAMs, with an average availability rate of approximately 1.01% nationwide, were included. There were significant differences between provinces for each drug, and the availability of NRAMs gradually decreased in tertiary (13.41%), secondary (1.58%), and primary medical institutions (< 0.05%). Differences were also observed in the availability rate of NRAMs in various daily drug cost ranges. Among the factors examined, negotiation access time (r The low availability of NRAMs in national and provincial medical institutions indicates that their willingness to equip NRAMs needs to be improved. All factors examined in this study affected the availability of NRAMs. Our findings can guide policymakers in improving relevant policies.
Sections du résumé
BACKGROUND
BACKGROUND
High clinical value national reimbursement anticancer medications (NRAMs) are pivotal treatments for patients with cancer. However, the availability of NRAMs in medical institutions is unknown. This study aimed to assess the availability of NRAMs in national and provincial medical institutions.
METHODS
METHODS
This cross-sectional study utilized national health insurance data to access the availability of NRAMs in national and provincial medical institutions. Further statistical analyses and visualizations were conducted in terms of medical institution level and daily cost. Using the Spearman's rank correlation test (α = 0.05), we calculated the correlation between the availability rates of NRAMs and their negotiation access time, daily cost, per capita disposable income, provincial gross product, and number of policy releases.
RESULTS
RESULTS
Overall, 81 NRAMs, with an average availability rate of approximately 1.01% nationwide, were included. There were significant differences between provinces for each drug, and the availability of NRAMs gradually decreased in tertiary (13.41%), secondary (1.58%), and primary medical institutions (< 0.05%). Differences were also observed in the availability rate of NRAMs in various daily drug cost ranges. Among the factors examined, negotiation access time (r
CONCLUSIONS
CONCLUSIONS
The low availability of NRAMs in national and provincial medical institutions indicates that their willingness to equip NRAMs needs to be improved. All factors examined in this study affected the availability of NRAMs. Our findings can guide policymakers in improving relevant policies.
Identifiants
pubmed: 39169407
doi: 10.1186/s12889-024-19786-y
pii: 10.1186/s12889-024-19786-y
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2268Informations de copyright
© 2024. The Author(s).
Références
Global Burden of Disease Study 2019. (GBD 2019) Results. Global Burden of Disease Collaborative Network. 2023. https://vizhub.healthdata.org/gbdresults/ . Accessed 8 Dec 2023.
Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018. https://doi.org/10.1016/S2214-109X(18)30127-X
pubmed: 29653628
doi: 10.1016/S2214-109X(18)30127-X
Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660
pubmed: 33538338
doi: 10.3322/caac.21660
Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47–53. https://doi.org/10.1016/j.jncc.2024.01.006
pubmed: 39036382
pmcid: 11256708
doi: 10.1016/j.jncc.2024.01.006
Global Oncology Trends 2023. IQVIA. 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2023 . Accessed 21 Dec 2023.
Shanlian H. Review and outlook of China’s health insurance drug price negotiation[J]. Health Econ Res 2024,41(01):9–13. https://doi.org/10.14055/j.cnki.33-1056/f.2024.01.003
Chen Y, Dong H, Wei Y, Yang Y, Ming J, Yu H. Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy. BMJ. 2023;381:e069963. https://doi.org/10.1136/bmj-2022-069963
pubmed: 37321628
pmcid: 10266439
doi: 10.1136/bmj-2022-069963
Statistical bulletin on the development of national healthcare security in 2022. National Healthcare Security Administration. 2023. http://www.nhsa.gov.cn/art/2023/7/10/art_7_10995.html . Accessed 26 Sept 2023.
Liqiu C, Lixiong Y. Analysis of changes in negotiated drugs in the national medical insurance catalog agreement period from 2019 to 2022. Straits Pharmacol. 2023;35:94–7.
Interpretation of the policy on issuing the notice of the national basic medical insurance, work injury insurance, and maternity insurance drug list. (2022). National Healthcare Security Administration. 2023. http://www.nhsa.gov.cn/art/2023/1/18/art_105_10081.html . Accessed 26 Sept 2023.
Yuhang L, Zijin W, Yao D, et al. Research on the accessibility of national reimbursement drugs based on multidimensional scaling analysis. China Hosp Manage. 2023;43:25–9.
Libo T, Yao W. Analysis of the landing issues of national reimbursement drugs from the perspective of transaction costs. Health Soft Sci. 2022;36:67–70.
Lingling C, Wei X, Bobo S, et al. Research on the accessibility of national reimbursement drugs: an empirical analysis based on purchasing data from public hospitals in Suzhou city. Health Econ Res. 2020. https://doi.org/10.14055/j.cnki.33-1056/f.2020.12.005
doi: 10.14055/j.cnki.33-1056/f.2020.12.005
Dengzi Z, Yushui L, Chun C, et al. Investigation and empirical analysis of the implementation of national reimbursement drug policies in Fujian province: based on centralized procurement and special drugstore data. China Med Insurance. 2021. https://doi.org/10.19546/j.issn.1674-3830.2021.10.002
doi: 10.19546/j.issn.1674-3830.2021.10.002
Kaijie L, Yingting L, Xiaoyuan F, et al. Study on the accessibility of national reimbursement access drugs. China Med Insurance. 2023. https://doi.org/10.19546/j.issn.1674-3830.2023.1.003
doi: 10.19546/j.issn.1674-3830.2023.1.003
Wei L, Hongdou C, Wei L, et al. China Mod Appl Pharm. 2023. https://doi.org/10.13748/j.cnki.issn1007-7693.20222377 . Study on the accessibility of national medical insurance negotiated drugs from 2016 to 2021: An empirical analysis based on national big data.
Qipeng F, Haoming L. Application status and accessibility analysis of Shandong province’s medical insurance negotiated drugs. China Med Insurance. 2022. https://doi.org/10.19546/j.issn.1674-3830.2022.9.025
doi: 10.19546/j.issn.1674-3830.2022.9.025
Yuan S, Ying Y, Lining M, et al. Current situation of purchasing and utilization of national reimbursement drugs in public medical institutions in China: an empirical data analysis from 13 regions. China Health Resour. 2022. https://doi.org/10.13688/j.cnki.chr.2022.210797
doi: 10.13688/j.cnki.chr.2022.210797
Li BX, Wang YQ, Yi YY, Zhou N, Lv ZX, Ma R, Li X, Yuan N. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data. BMC Public Health. 2024;24(1):1309. https://doi.org/10.1186/s12889-024-18820-3
pubmed: 38745323
pmcid: 11092061
doi: 10.1186/s12889-024-18820-3
Zhiguo Q, Lei K, Yuansheng W, et al. Current status and influencing factors of accessibility of national reimbursement drugs in a hospital. Chin J Hosp Pharm. 2022. https://doi.org/10.13286/j.1001-5213.2022.18.12
doi: 10.13286/j.1001-5213.2022.18.12
Cai L, Tao T, Li H, et al. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study. J Glob Health. 2022. https://doi.org/10.7189/jogh.12.11016
pubmed: 36527382
pmcid: 9758701
doi: 10.7189/jogh.12.11016
Guiding opinions on promoting the construction of hierarchical medical system. State Council General Office. 2023. https://www.gov.cn/zhengce/content/2015-09/11/content_10158.htm . Accessed 18 Dec 2023.
Lifu C, Weiying D, Minling X, et al. Practice of multidisciplinary collaborative palliative care in terminally ill cancer patients in a tertiary comprehensive hospital. J Nurs. 2020. https://doi.org/10.16460/j.issn1008-9969.2020.15.056
doi: 10.16460/j.issn1008-9969.2020.15.056
Notice on the implementation of 17 national reimbursement anticancer medicines. National Healthcare Security Administration. 2023. http://www.nhsa.gov.cn/art/2018/11/21/art_19_394.html . Accessed 17 Dec 2023.
Notice on the implementation of national reimbursement drugs in 2019. National Healthcare Security Administration. 2023. http://www.nhsa.gov.cn/art/2019/12/18/art_53_2182.html . Accessed 17 Dec 2023.
Notice on adapting to the normalization of national healthcare security negotiations and continuously doing well in the implementation of negotiated drugs. National Healthcare Security Administration. 2023. https://www.gov.cn/zhengce/zhengceku/2021-09/11/content_5636762.htm . Accessed 17 Dec 2023.
Fan Wu. Smooth the last kilometer of the national reimbursement drug landing. China Health 2023(03):32 https://doi.org/10.15973/j.cnki.cn11-3708/d.2023.03.026
Moye-Holz D, van Dijk JP, Reijneveld SA, et al. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 innovative Cancer Medicines in a Middle-Income Country: the case of Mexico. Value Health Reg Issues. 2019. https://doi.org/10.1016/j.vhri.2019.04.006
pubmed: 31374426
doi: 10.1016/j.vhri.2019.04.006
Rui S, Zhimei X, Yue L, et al. Research on accessibility and affordability of antitumor drugs in public hospitals: data analysis based on a typical survey of public hospitals in Jiangsu Province. Price Theory Pract. 2019. https://doi.org/10.19851/j.cnki.cn11-1010/f.2019.05.010
doi: 10.19851/j.cnki.cn11-1010/f.2019.05.010
Huang C, Ung COL, Wushouer H, et al. Trends of Negotiated targeted Anticancer Medicines Use in China: an interrupted Time Series Analysis. Int J Health Policy Manag. 2022. https://doi.org/10.34172/ijhpm.2021.47
pubmed: 35247942
pmcid: 9818124
doi: 10.34172/ijhpm.2021.47
Zhao Y, Zhang L, Fu Y, et al. Socioeconomic disparities in Cancer Treatment, Service utilization and Catastrophic Health expenditure in China: a cross-sectional analysis. Int J Environ Res Public Health. 2020. https://doi.org/10.3390/ijerph17041327
pubmed: 33375631
pmcid: 7794919
doi: 10.3390/ijerph17041327
Fang P, Dong S, Xiao J, et al. Regional inequality in health and its determinants: evidence from China. Health Policy. 2010. https://doi.org/10.1016/j.healthpol.2009.08.002
pubmed: 19833405
doi: 10.1016/j.healthpol.2009.08.002
Zhao Y, Tang S, Mao W, et al. Socio-Economic and Rural-Urban Differences in Healthcare and Catastrophic Health Expenditure among Cancer patients in China: analysis of the China Health and Retirement Longitudinal Study. Front Public Health. 2022. https://doi.org/10.3389/fpubh.2021.779285
pubmed: 36845347
pmcid: 9807660
doi: 10.3389/fpubh.2021.779285
Yingqi Liu. Research on Poverty Reduction Effect of Serious Illness Insurance for Urban and rural residents: analyses based on different groups. Dongbei Univ Finance Econ. 2023. https://doi.org/10.27006/d.cnki.gdbcu.2023.000395
doi: 10.27006/d.cnki.gdbcu.2023.000395
H Rui. Research on local government emergency management of public health emergencies based on policy texts. Shanxi Univ Finance Econ. 2022. https://doi.org/10.27283/d.cnki.gsxcc.2022.000206
doi: 10.27283/d.cnki.gsxcc.2022.000206
L Huikang. Textual measurement and efficiency evaluation of new energy industry policies. Shandong Univ Finance Econ. 2022. https://doi.org/10.27274/d.cnki.gsdjc.2022.000517
doi: 10.27274/d.cnki.gsdjc.2022.000517